ACI
SGMO

AMP Capital Investors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

AMP Capital Investors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-17,200
Closed -$339K – 1218
2018
Q1 		$339K Buy
+17,200
New +$368K ﹤0.01% 1055

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AMP Capital Investors's SGMO Position: Q2 2018 in Review

AMP Capital Investors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 17,200 shares — an estimated $339K sold.

AMP Capital Investors first reported a position in SGMO in Q1 2018 and held it in 1 quarter. The position peaked at $339K in Q1 2018. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

  • AMP Capital Investors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
  • AMP Capital Investors sold 17,200 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $339K.
  • AMP Capital Investors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 1 quarter.
  • AMP Capital Investors's SANGAMO THERAPEUTICS INC position peaked at $339K in Q1 2018.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on AMP Capital Investors's 13F filing for Q2 2018, filed 13 Aug 2018.